Theravance Biopharma, Inc. (TBPH) Institutional Ownership

Ownership Summary

Theravance Biopharma, Inc. (NASDAQ:TBPH) appears in 166 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 95.5% of Theravance Biopharma's outstanding shares in December 2025, up from 94.8% in September 2025.
• They increased total shares held in TBPH by 2.17% quarter over quarter, and investors in Theravance Biopharma increased 30.71% from a year ago.
• Of these 166 funds, 95 grew their exposure to Theravance Biopharma, 47 cut back, and 24 maintained positions.
• In total, institutional investors held 49.56Mn shares in Theravance Biopharma as of December 2025, up by 1.05Mn shares quarter on quarter, and up 4.13Mn shares year over year.
• Madison Avenue Partners, LP is the top holder of Theravance Biopharma as of December 31, 2025, with 9.51Mn shares representing 18.32% of outstanding stock.
• The largest buyers of Theravance Biopharma for the quarter ending December 2025 were VANGUARD CAPITAL MANAGEMENT LLC (1.78Mn), TWO SIGMA INVESTMENTS, LP (721.16K), Newtyn Management, LLC (541.63K), VANGUARD PORTFOLIO MANAGEMENT LLC (400.76K), Janus Henderson Group Plc (357.46K).
• Leading sellers of Theravance Biopharma shares for the quarter ending December 2025 were ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (635.71K), D. E. Shaw & Co., Inc. (305.9K), Morgan Stanley (292.85K), Jpmorgan Chase & Co (289.14K), MARSHALL WACE, LLP (259.73K).
• Theravance Biopharma's 10 largest shareholders as of December 2025 include Madison Avenue Partners, LP (9.51Mn), Weiss Asset Management LP (7.46Mn), Newtyn Management, LLC (4.84Mn), BlackRock, Inc. (4.3Mn), Irenic Capital Management LP (2.76Mn), VANGUARD CAPITAL MANAGEMENT LLC (1.78Mn), State Street Corp (1.3Mn), ACADIAN ASSET MANAGEMENT LLC (1.28Mn), TWO SIGMA INVESTMENTS, LP (1.26Mn), GEODE CAPITAL MANAGEMENT, LLC (1.14Mn) per Business Quant data.